Day: November 7, 2025

LAS VEGAS, Nov. 07, 2025 (GLOBE NEWSWIRE) — GBank Financial Holdings Inc. (the “Company”) (Nasdaq: GBFH), the parent company of GBank (the “Bank”), is pleased to announce that Hilary R. Sledge-Sarnor has been appointed Executive Vice President, General Counsel, and Corporate Secretary of the Company and the Bank, effective October 20, 2025. In this role, Ms. Sledge-Sarnor will oversee the Company’s and Bank’s legal, corporate governance, and regulatory affairs functions, serving as a key strategic advisor to executive management and the Board of Directors. She will also play a central role in supporting the Company’s continued growth initiatives, capital markets activities, and evolving FinTech partnerships. Ms. Sledge-Sarnor joins GBank from Greenberg Traurig, LLP, where she was a Shareholder in the Financial Regulatory and Compliance...

BELVIDERE, NJ, Nov. 07, 2025 (GLOBE NEWSWIRE) — Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leader in controlled environment agriculture (CEA), locally grown, organic, better-for-you, sustainable produce and products, announced today that it will host a conference call on Friday, November 14, 2025, at 8:00 AM Eastern Time to discuss financial results for the 2025 third quarter and provide a business update. The conference call will be available via telephone by dialing toll-free +1 808-506-0062 for U.S. callers or +1 973-528-0011 for international callers and entering access code 547767. A webcast of the call may be accessed at https://www.webcaster4.com/Webcast/Page/2914/53224 or on the investor relations section of the company’s website, https://ediblegardenag.com/presentations/. A...

LAS VEGAS, Nov. 07, 2025 (GLOBE NEWSWIRE) — Jet.AI Inc. (“Jet.AI” or the “Company”) (Nasdaq: JTAI) and Consensus Core Technologies Inc. (“Consensus Core”), a leader in high-performance GPU infrastructure and AI cloud services, today announced that the second milestone has been substantially completed for their hyperscale data center campus in Midwestern Canada (the “Midwestern Project”) and Maritime Canada (the “Maritime Project”), respectively. The completed second milestone includes the following:Contribution of $1.7 million by Jet.AI to the joint venture Release of mortgage liens of the existing acreage owned by the Midwestern Project Execution of a Letter of Intent to acquire 350 acres of property adjacent to the existing property owned by the Midwestern Project (a significantly larger...

Company prepares for first Easy FEN™ system deployment in Africa as part of global expansion strategy MANKATO, Minn., Nov. 07, 2025 (GLOBE NEWSWIRE) — Easy Environmental Solutions, Inc. (OTC: EZES) (“Easy Environmental” or the “Company”), formerly known as Digital Utilities Ventures, Inc., today announced that its common stock has begun trading under the new ticker symbol EZES. The new symbol reflects the completion of the Company’s previously announced name change and corporate rebranding, marking another key milestone in its evolution as a leader in sustainable modular technologies. With these initiatives now complete, Easy Environmental is planning to uplist to the OTCQB Venture Market and preparing for the first commercial deployment of its Easy FEN™ system in Africa, scheduled for early 2026. “Our transition...

AB Amber Grid delivers results for 9 months of 2025 prepared according to the International Financial Reporting Standards:• Revenue for 9 months of 2025 EUR 49.5 million (9 months of 2024 EUR 51.6 million);• Net profit for 9 months of 2025 EUR 1.5 million (9 months of 2024 EUR 5.7 million);• EBITDA (earnings before interest, taxes, depreciation and amortisation) for 9 months of 2025 EUR 14.7 million (9 months of 2024 EUR 19.0 million);• Average return on equity (ROE) for the last 12 month as of 30 September 2025 2.4% (as of 30 September 2024 1.8%). AB Amber Grid adjusted financial indicators for 9 months of 2025:• Adjusted net profit for 9 months of 2025 EUR 9.4 million (9 months of 2024 EUR 7.7 million);• Adjusted EBITDA (earnings before interest, taxes, depreciation and amortisation) for 9 months of 2025 EUR 22.8 million (9 months...

40% ORR in heavily pre-treated patients with MSS mCRC without liver metastases and with high plasma tumor mutational burden (TMB) Estimate 55% of patients with MSS CRC have high plasma TMB, representing a meaningful population with high unmet need Company to host conference call and webcast on Monday, November 10, 2025, at 4:30 p.m. ET with leading cancer experts to review the data WALTHAM, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) — Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced new data from its ongoing Phase 2 clinical trial evaluating vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab (Tecentriq®) in patients with microsatellite stable (MSS) metastatic...

Second Campus in the Dallas Metro Area to Address Underserved Market for Electrical, HVAC, Automotive and Welding Skills Training Parsippany, NJ, Nov. 07, 2025 (GLOBE NEWSWIRE) — Lincoln Educational Services Corporation (Nasdaq: LINC), a national leader in specialized technical and skills training for nearly 80 years, today announced plans to expand its presence in Texas with a second campus in the metropolitan Dallas area. The Company’s 24th campus will be in Rowlett, TX, a northern suburb conveniently located near major interstate (635 and 30) highways and will complement the highly successful Lincoln campus in Grand Prairie, Texas. The new 88,000 square foot campus will offer automotive, welding, electrical and HVAC training, playing a pivotal role in filling more than 240,000 anticipated job openings in these fields across...

Preclinical data support best-in-class potential of masked T cell engager programs and platform utilizing Xilio’s ATACR and SEECR formats, including efficient masking, potent anti-tumor activity and broad therapeutic index Phase 1 data for efarindodekin alfa, a tumor-activated IL-12, demonstrated promising monotherapy anti-tumor activity in patients with advanced solid tumors and generally well-tolerated safety profile Phase 2 data for vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4, show potential for ctDNA as an early predictor for response to treatment with vilastobart in combination with atezolizumab in patients with MSS mCRC WALTHAM, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) — Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies...